Pfizer Q3 Review - Core Brands Growth To Rise, Valuation Attractive: Anand Rathi
A healthcare worker holds a vial of the Pfizer-BioNTech Covid-19 vaccine in a care home in Paris, France (Photographer Nathan Laine/Bloomberg)

Pfizer Q3 Review - Core Brands Growth To Rise, Valuation Attractive: Anand Rathi

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Report

On its better hospitals and vaccine performances, Pfizer Ltd.’s Q3 FY21 sales grew 10.3% YoY to Rs 5.9 billion.

Its gross margin expanded 149 basis points YoY to 64.2%, while the Ebitda margin expanded 836 basis points YoY to 33.2% on account of lower promotional costs.

Lower other income and a higher tax rate reduced adjusted profit after tax growth to 19.8% (Rs 1.4 billion).

We expect sales growth of key brands (Gelusil, Prevenar-13, Becosules, Magnex, Dolonex and Meronem) to accelerate in FY22.

Click on the attachment to read the full report:

Anand Rathi Pfizer Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.